U.S. markets open in 1 hour 11 minutes
  • S&P Futures

    4,203.50
    -18.75 (-0.44%)
     
  • Dow Futures

    33,617.00
    -188.00 (-0.56%)
     
  • Nasdaq Futures

    14,137.75
    -27.75 (-0.20%)
     
  • Russell 2000 Futures

    2,264.30
    -20.20 (-0.88%)
     
  • Crude Oil

    70.33
    -0.71 (-1.00%)
     
  • Gold

    1,792.70
    +17.90 (+1.01%)
     
  • Silver

    26.37
    +0.51 (+1.99%)
     
  • EUR/USD

    1.1896
    -0.0014 (-0.12%)
     
  • 10-Yr Bond

    1.5110
    0.0000 (0.00%)
     
  • Vix

    19.26
    +1.11 (+6.12%)
     
  • GBP/USD

    1.3869
    -0.0055 (-0.40%)
     
  • USD/JPY

    110.1980
    -0.0330 (-0.03%)
     
  • BTC-USD

    37,525.01
    -1,303.75 (-3.36%)
     
  • CMC Crypto 200

    928.13
    -41.75 (-4.30%)
     
  • FTSE 100

    7,060.48
    -92.95 (-1.30%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Ascendis Pharma: Q2 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Ascendis Pharma (NASDAQ:ASND) were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share were down 56.12% year over year to ($2.17), which missed the estimate of ($1.70).

Revenue of $1,581,000 declined by 55.64% year over year, which missed the estimate of $2,530,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Aug 27, 2020

View more earnings on ASND

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/w7hnzp6j

Technicals

Company's 52-week high was at $158.93

Company's 52-week low was at $90.06

Price action over last quarter: down 5.18%

Company Profile

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in the USA, Germany, and Switzerland and derives the majority of its revenue from the US.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.